-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on NovoCure, Lowers Price Target to $27

Benzinga·04/16/2025 14:08:25
Listen to the news
Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and lowers the price target from $29 to $27.